NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
- Conditions
- Skin AngiosarcomaVisceral AngiosarcomaSkin Radiation-Related Angiosarcoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: FDG-Positron Emission TomographyProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT04339738
- Locations
- 🇺🇸
Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT04334941
- Locations
- 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
- Conditions
- Histologically or Cytologically Confirmed Pancreatic CancerUnresectable or Borderline Resectable Pancreatic CancerPancreatic NeoplasmsPancreatic CancerMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT04327986
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT04324112
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT04322383
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
- Conditions
- Refractory Histiocytic and Dendritic Cell NeoplasmRecurrent EpendymomaRecurrent Histiocytic and Dendritic Cell NeoplasmRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Malignant GliomaRecurrent Malignant Solid NeoplasmRecurrent RhabdomyosarcomaRecurrent WHO Grade 2 GliomaRefractory Malignant Germ Cell Tumor
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04320888
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Sacred Heart Hospital, Pensacola, Florida, United States
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
- Conditions
- Unresectable Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 102
- Registration Number
- NCT04317105
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
National Cancer Institute "Cancer Moonshot Biobank"
- Conditions
- Acute Myeloid LeukemiaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Invasive Breast CarcinomaLung Small Cell CarcinomaPrimary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionOther: Medical Chart Review
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1000
- Registration Number
- NCT04314401
- Locations
- 🇺🇸
Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography Test
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 117
- Registration Number
- NCT04310007
- Locations
- 🇺🇸
Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States
🇺🇸Saint Joseph Hospital, Lexington, Kentucky, United States
🇺🇸Bronson Battle Creek, Battle Creek, Michigan, United States
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
- Conditions
- Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyRadiation: Hypofractionated Radiation TherapyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT04310020
- Locations
- 🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States